Project Grant K99CA307134
Award Date 9/2/26
Completion Date 8/31/28
Dollars Obligated $130K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- The National Cancer Institute awarded Northwestern University $496,357 under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, to investigate mechanisms of immunosuppression in glioblastoma and develop therapeutic interventions targeting tumor-associated macrophage polarization. The research centers on the peri-necrotic niche within IDH-wildtype glioblastoma tumors, where hypoxic glioma cells and immunosuppressive tumor-associated macrophages aggregate in spatial...
- The National Cancer Institute awarded $443,052 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of the WNK1 kinase in glioblastoma progression and therapeutic resistance. The research focuses on mechanistic insight into how WNK1 drives glioblastoma growth through both kinase-dependent and kinase-independent pathways. Preliminary data show that glioblastoma cancer...
- The National Cancer Institute awarded The Ohio State University $567,754 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on immunotherapy for glioblastoma by targeting an immunoregulatory neuropeptide. The research addresses glioblastoma (GBM), the most lethal primary brain tumor, which exhibits remarkable resistance to immunotherapy due to CD8 T cell exclusion and dysfunction driven by immunosuppressive myeloid cells, particularly tumor-associated...
- The National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $640,775 on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a co-clinical trial investigating mechanisms by which intratumoral bacteria drive immunosuppression and immune checkpoint inhibitor resistance in head and neck squamous cell carcinoma. The recipient will define how intratumoral bacterial load modulates the immunosuppressive tumor immune...
- This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded The Trustees of the University of Pennsylvania $594,899 on July 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to fund research on vascular regulation of macrophage function in glioblastoma. The research addresses the immunosuppressive microenvironment in glioblastoma, the most common and aggressive malignant primary brain tumor in adults, which is largely refractory to T cell-based immunotherapies. The project uses single-cell...